Latest news with #PRISM
National Post
a day ago
- Business
- National Post
Zero Networks Earns Platinum Rating in EMA PRISM Report for Microsegmentation
Article content – Article content Article content set to be demonstrated live at Black Hat USA Article content – Article content strengthens Zero Networks' market leadership Article content ORLANDO, Fla. — Zero Networks, a leading provider of zero trust security solutions, was awarded a Platinum rating in the June 2025 'EMA™ PRISM Report – Microsegmentation.' Platinum is the highest possible ranking in the PRISM report and is based on a detailed evaluation of the following criteria: product and functionality, integrations and operability, and strength and maturity. The report summarizes Zero's key differentiators as simplicity and efficiency, real-time network awareness, and scalability. Article content Specifically, EMA VP of Research, Christopher Steffen, stated: 'The platform shows a commitment to ongoing development, focusing on scalable solutions that address the complexities of modern network environments. With strong product backing and a vision that aligns with the growing need for stringent network security measures, Zero Networks is establishing itself as a mature player in the market.' Article content Unlike traditional perimeter-based security, which focuses on keeping threats out, microsegmentation assumes breaches can and will occur, and aims to contain them swiftly within a defined segment, preventing widespread damage. Zero's unique capabilities include automated policy creation and provisioning, agentless architecture, and dynamic and adaptive management. This means faster time to value, no deployment friction, and continuous protection that evolves with your environment. Download EMA's full Solution Profile of Zero Networks here. Article content 'Zero Networks is proud to be recognized with a Platinum rating in the EMA™ PRISM Report for Microsegmentation,' said Benny Lakunishok, CEO of Zero Networks. 'While competitors require large teams and constant attention to deliver only partial protection, Zero Networks is leading the industry with a solution that is simple to deploy, enforce, and manage. This recognition by EMA reflects our team's commitment to eliminating complexity and operational burden for security teams—and empowering organizations of any size to finally harness the full potential of microsegmentation.' Article content Zero Networks is Live at Black Hat USA, Booth #2251 Article content Zero Networks is bringing radically simple microsegmentation to Black Hat USA 2025 (Aug. 5-7, 2025) with hands-on demos, expert-led sessions, and a calming booth experience that proves security doesn't have to be chaotic. Here are all the ways to engage with Zero Networks on site at Black Hat: Article content Visit the team at Booth #2251 to see their solutions in action, hear directly from Zero customers, and learn about their powerful technology partnerships. For example: Zero Networks' Visibility Map (Wednesday, Aug. 6 at 5:00-5:15 pm) – Find out how Zero Networks is rewriting the microsegmentation playbook, making visualization a helpful tool for validation and investigation—not a prerequisite for implementation. This is a live demonstration of our Visibility Map, an intuitive tool designed to streamline how you explore network assets, activities, and segmentation policies. Expanding Microsegmentation to Kubernetes (Thursday, Aug. 7 at 12:00-12:15 pm) – Get a firsthand look at how Zero Networks is bringing effortless microsegmentation to Kubernetes environments. Learn how our solution discovers in-cluster resources, monitors internal and external activity, and enforces segmentation across workloads, applications, and other K8s entities. Better Together: Zero Networks + Palo Alto Networks (Thursday, Aug. 7 at 2:00-2:15pm) – Explore how Zero Networks and Palo Alto Networks join forces to deliver a powerful, integrated defense that blocks lateral movement and ransomware while simplifying your security stack. Presented by Jasmine Punia, Senior Product Manager at Palo Alto Networks. Catch Zero Networks on the Black Hat stage on Wednesday, Aug. 6, at 2:40pm at Business Hall Theater E – CTO Amir Frankel and VP Customers Nicholas DiCola will present: ' The Microsegmentation Project You Can Actually Complete: Shifting Security's Burden Back to Attackers.' Join Zero for a happy hour at Sbar, Mandalay Bay on Tuesday, Aug. 5 ( RSVP), or escape the chaos of the tradeshow floor by relaxing and recharging in their booth's 'Zen Zone' silent disco. To schedule a meeting or view the daily booth presentation schedule, visit: Article content If you won't be at Black Hat, take a self-guided product tour via Zero's virtual, hands-on demo environment to experience radically simple implementation and set-and-forget management. Article content About Zero Networks Article content Zero Networks is revolutionizing network security with its effortless microsegmentation solution that stops ransomware and implements in days, not years. By automating asset tagging and policy creation, Zero Networks saves enterprises an average of 86% on total cost of ownership compared to legacy microsegmentation solutions that rely on time-intensive manual processes. Combined with advanced Identity Segmentation and Zero Trust Network Access solutions, and fortified by network-layer MFA, Zero Networks' platform accelerates zero trust initiatives at companies of any size. This comprehensive approach enables organizations to stop lateral movement attacks, exceed compliance requirements, achieve top-tier audit scores, and pass every penetration test. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Article content
Time of India
3 days ago
- Business
- Time of India
From saving girls to training artisans: Kolkata's 'Nexus of Good' showcases inspiring work
PRISM is combating human trafficking in Alipurduar's tea gardens, while KADAM HAAT empowers artisans through training and market access, aiming for global recognition. Anondolok provides support to the homeless in North 24 Parganas. These organizations were showcased at a 'Nexus of Good' event, promoting positive work and inspiring replication of successful models like KADAM HAAT. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads An organization works for women's empowerment, making rural-road savvy ambulances, clean drinking water for people and works against trafficking of women from the teagarden belt of Alipurduar. PRISM, the organization, was instrumental in recently stopping trafficking of 56 young girls, who were lured from the tea-garden belt, for jobs and rescued by police following action by this Dhar told ET the stories about how post-pandemic, the economy of the teagarden belt of Alipurduar has suffered leading to increased trafficking of women. PRISM works in close coordination with District Magistrate, SDO, CMOH and Gram Panchayats in North Bengal. KADAM HAAT is another organization which trains artisans and helps them get market access. The organization has already trained 10,000 artisans across the country and has commercialized it. The products are available and the artisans get benefit of the market linkages. Mirnal Jain, young founding member, who is 26, and COO of KADAM HAAT, said that he will make the organization a global brand in next five years and train 30,000 more artisans from all across the said that he sees the artisans as 'micro-entrepreneurs' doing handmade work which has become popular another organization, works for the homeless and has been serving people for the last 33 years from North 24 Parganas district's three organizations did the storytelling of empowerment and positive work, as part of a programme of the Kolkata chapter of ' Nexus of Good ', a concept floated by former IAS Anil Swarup, which promotes positive work and developmental ideas. Swarup believes in building a 'Nexus of Good' movement by 'identifying, appreciating, propagating and replicating good work'.Swarup said that taking inspiration from KADAM, the idea can be replicated in other organizations and it can develop as a sustainable model . 'KADAM is truly remarkable and the model can work in many other organizations. PRISM is also doing wonderful work while Anondolok was another example of good work.' Kolkata chapter was formed recently and today was second meeting of the chapter of 'Nexus of Good'.
Yahoo
11-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 4, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE), retaining the price target of $24.00. A biotechnology laboratory filled with computers and equipment to support research. The analyst supported the rating with the company's promising developments in RNA editing, especially in the treatment for alpha-1-antitrypsin deficiency (AATD). He reasoned that the initial human data for the company's WVE-006 compound exhibited optimistic results, as patients reached notable levels of AAT protein after a single low dose. According to Schwartz, this breakthrough marks a significant milestone for Wave Life Sciences Ltd. (NASDAQ:WVE) while also setting a precedent for the broader RNA editing domain. He expects the upcoming data readouts to have further positive outcomes and anticipates a dose-dependent rise in efficacy with an increase in dosage. The analyst also stated that the potential to exceed the established 11 µM threshold for AAT protein, and even approach normal healthy levels, may cause a considerable boost to the stock's value. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that develops and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. PRISM combines a deep understanding of human genetics with chemistry innovation and multiple modalities for scientific discoveries and breakthroughs that treat prevalent and rare disorders. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Wire
08-07-2025
- Health
- Business Wire
BostonGene Announces Collaboration with SWOG Cancer Research Network to Drive Personalized Approaches
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced a collaboration with the SWOG Cancer Research Network, a global cancer research community that designs and conducts publicly funded clinical trials, on a new multicohort study titled " S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)." This study, which is supported by the National Cancer Institute (NCI), part of the National Institutes of Health, aims to redefine the standard of care for patients with ES-SCLC by employing biomarker-driven personalized treatment strategies. 'By combining advanced molecular profiling with AI, we're not only able to classify patients more precisely but also to advance therapy selection and accelerate the development of next-generation treatments." Currently, the standard treatment for ES-SCLC involves combination chemotherapy and anti-PD-L1 immunotherapy, followed by maintenance immunotherapy. While this broad approach extends overall survival by 2-3 months, it still results in disease progression in most patients. The PRISM study is designed to utilize novel biomarkers to identify and treat patients who may benefit from the addition of targeted agents, such as PARP inhibitors, to standard therapy. The study will be led by SWOG, conducted within the NCI's National Clinical Trials Network, and chaired by Drs. Anne Chiang, of the Yale Cancer Center, and Alberto Chiappori, of the Moffitt Cancer Center, in conjunction with Translational Medicine chairs Drs. Lauren Byers and Carl Gay, of The University of Texas MD Anderson Cancer Center. The trial will enroll up to 900 patients and use BostonGene's AI-powered multiomic platform to identify molecular subtypes, assigning patients to therapy based on their subtype. The platform enables deep characterization of each patient's tumor and immune profile, supporting the selection of more effective therapies and helping to accelerate translational insights that inform future drug development. The trial builds on the ongoing collaborative work between MD Anderson's lung cancer group, including Drs. Byers and Gay, and BostonGene to identify and validate four molecular subtypes of SCLC that exhibit distinct biological and therapeutic profiles. Initial findings from the SWOG S1929 trial demonstrated promising improvements in progression-free survival using this targeted approach. The goal of the upcoming study is to optimize outcomes for each subtype, offering patients more effective and individualized treatments. 'S2409 PRISM will test the hypothesis that we can be more effective in treating extensive-stage small-cell lung cancer by targeting the vulnerabilities of specific molecular subtypes,' said study chair Dr. Chiang, who also serves as SWOG's executive officer overseeing lung cancer and breast cancer research. 'We hope to demonstrate that it's feasible to identify the SCLC subtype in the clinical setting and to use that information to select the best therapy for each patient.' 'Collaborating with SWOG on this landmark study aligns with our mission to deliver innovative, data-driven insights that are transforming cancer care,' said Nathan Fowler, MD, Chief Medical Officer at BostonGene. 'By combining advanced molecular profiling with AI, we're not only able to classify patients more precisely but also to advance therapy selection and accelerate the development of next-generation treatments. This study is poised to reshape the treatment landscape in lung cancer and provide a roadmap of how to build and validate biomarker-driven treatment approaches across cancers.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
Business Wire
07-07-2025
- Business
- Business Wire
Mitsubishi Electric's ME Innovation Fund Invests in AI-assisted PLM Systems Startup 'Things'
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Things, Inc., a Japan-based startup that develops and provides AI-assisted product lifecycle management (PLM) systems for manufacturing, specializing in comprehensive document management from product planning to development to disposal. This is the twelfth investment that the fund has made to date. Through this investment, Mitsubishi Electric aims to integrate its extensive manufacturing and control expertise with Things' generative AI technology to accelerate the development of digital transformation (DX) solutions that address various manufacturing challenges. In recent years, Japan's manufacturing industry has faced labor shortages, the aging of skilled technicians and other challenges that are inhibiting skills transfer. In response, DX initiatives such as the implementation of PLM and other digital systems have advanced rapidly, but have encountered issues regarding development time, cost, usability and scalability. Things introduced its 'PRISM' PLM system in May 2023 to leverage generative AI to improve the structure and usage of information in manufacturing. PRISM offers significant cost and scalability advantages for enhancing user interfaces and experiences, and for effectively implementing proofs of concept (PoCs) across a wide range of companies.
